CFDE Data Portal | Search SERPINB2

	Label	Description
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 1 V 3 PROGESTERONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	SERPINB2 associations Collection (Entity type)	Associations for SERPINB2_associations
	GSE135030 3 V 10 FLUDARABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE220806 1 V 3 PROGESTERONE HUMAN UP

A Gene Set from LINCS

GSE195568 palbociclib 2 v 10 human up

A Gene Set from LINCS

SERPINB2 associations

Associations for SERPINB2_associations

GSE135030 3 V 10 FLUDARABINE HUMAN UP

A Gene Set from LINCS

GSE48812 sulforaphane 8 v 1 human dn

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.